- Home
- COLL vs BTX Comparison
COLL vs BTX Comparison
Compare COLL & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- BTX
- Stock Information
- Founded
- COLL 2002
- BTX N/A
- Country
- COLL United States
- BTX United States
- Employees
- COLL N/A
- BTX N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- BTX
- Sector
- COLL Health Care
- BTX
- Exchange
- COLL Nasdaq
- BTX Nasdaq
- Market Cap
- COLL 958.8M
- BTX 854.3M
- IPO Year
- COLL 2015
- BTX N/A
- Fundamental
- Price
- COLL $32.10
- BTX $6.76
- Analyst Decision
- COLL Strong Buy
- BTX
- Analyst Count
- COLL 4
- BTX 0
- Target Price
- COLL $44.25
- BTX N/A
- AVG Volume (30 Days)
- COLL 354.8K
- BTX 989.1K
- Earning Date
- COLL 11-06-2025
- BTX 11-01-2025
- Dividend Yield
- COLL N/A
- BTX 14.54%
- EPS Growth
- COLL N/A
- BTX N/A
- EPS
- COLL 1.06
- BTX N/A
- Revenue
- COLL $707,007,000.00
- BTX N/A
- Revenue This Year
- COLL $22.23
- BTX N/A
- Revenue Next Year
- COLL $2.78
- BTX N/A
- P/E Ratio
- COLL $31.21
- BTX N/A
- Revenue Growth
- COLL 22.61
- BTX N/A
- 52 Week Low
- COLL $23.23
- BTX $5.10
- 52 Week High
- COLL $39.95
- BTX $8.31
- Technical
- Relative Strength Index (RSI)
- COLL 30.71
- BTX 40.44
- Support Level
- COLL $34.19
- BTX $6.80
- Resistance Level
- COLL $35.83
- BTX $6.95
- Average True Range (ATR)
- COLL 1.05
- BTX 0.12
- MACD
- COLL -0.33
- BTX 0.01
- Stochastic Oscillator
- COLL 0.00
- BTX 35.71
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About BTX BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.